{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:04:05Z","timestamp":1790622245132,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02746-w","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:40:16Z","timestamp":1783060816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2380-1719","authenticated-orcid":false,"given":"Zhigang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangting","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-7955","authenticated-orcid":false,"given":"Xiaoming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-4134","authenticated-orcid":false,"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2746_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso, G., Weroha, S. J. & Cliby, W. Ovarian cancer: a review. JAMA 334, 1278\u20131291 (2025).","journal-title":"JAMA"},{"key":"2746_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb, P. M. & Jordan, S. J. Global epidemiology of epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 21, 389\u2013400 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2746_CR3","first-page":"436","volume":"75","author":"P Kordowitzki","year":"2025","unstructured":"Kordowitzki, P. et al. Transforming treatment paradigms: focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J. Clin. 75, 436\u2013460 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"2746_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1200\/JCO-24-02589","volume":"43","author":"S Gaillard","year":"2025","unstructured":"Gaillard, S. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 868\u2013891 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2746_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Immune checkpoint therapy for solid tumors: clinical dilemmas and future trends. Signal Transduct. Target Ther. 8, 320 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2746_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480\u2013489 (2011).","journal-title":"Nature"},{"key":"2746_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"2746_CR8","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomized, phase 3 study. Lancet Oncol. 22, 1034\u20131046 (2021).","journal-title":"Lancet Oncol."},{"key":"2746_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2025.03.005","volume":"43","author":"KE Pauken","year":"2025","unstructured":"Pauken, K. E., Alhalabi, O., Goswami, S. & Sharma, P. Neoadjuvant immune checkpoint therapy: enabling insights into fundamental human immunology and clinical benefit. Cancer Cell 43, 623\u2013640 (2025).","journal-title":"Cancer Cell"},{"key":"2746_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel, S. A. & Minn, A. J. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48, 417\u2013433 (2018).","journal-title":"Immunity"},{"key":"2746_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","volume":"12","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer. Cancer Discov. 12, 984\u20131001 (2022).","journal-title":"Cancer Discov."},{"key":"2746_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).","journal-title":"Science"},{"key":"2746_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","volume":"10","author":"M Sorin","year":"2024","unstructured":"Sorin, M. et al. Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis. JAMA Oncol. 10, 621\u2013633 (2024).","journal-title":"JAMA Oncol."},{"key":"2746_CR14","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2746_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee, A. & Keam, S. J. Tislelizumab: first approval. Drugs 80, 617\u2013624 (2020).","journal-title":"Drugs"},{"key":"2746_CR16","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu, M. Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-esophageal junction adenocarcinoma: RATIONALE-305 randomized, double blind, phase 3 trial. Br. Med. J. 385, e078876 (2024).","journal-title":"Br. Med. J."},{"key":"2746_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-092545","volume":"15","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y. et al. Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomized controlled trial. BMJ Open 15, e092545 (2025).","journal-title":"BMJ Open"},{"key":"2746_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943\u2013953 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2746_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe, S. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, noninferiority trial. Lancet 386, 249\u2013257 (2015).","journal-title":"Lancet"},{"key":"2746_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti, A. et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J. Gynecol. Cancer 30, 1657\u20131664 (2020).","journal-title":"Int J. Gynecol. Cancer"},{"key":"2746_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 34, 681\u2013692 (2023).","journal-title":"Ann. Oncol."},{"key":"2746_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46999-x","volume":"15","author":"IL Ray-Coquard","year":"2024","unstructured":"Ray-Coquard, I. L. et al. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nat. Commun. 15, 5931 (2024).","journal-title":"Nat. Commun."},{"key":"2746_CR23","doi-asserted-by":"publisher","first-page":"e007444","DOI":"10.1136\/jitc-2023-007444","volume":"11","author":"J Park","year":"2023","unstructured":"Park, J. et al. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046\/TRU-D. J. Immunother. Cancer 11, e007444 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2746_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"2746_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","volume":"43","author":"L Rausch","year":"2025","unstructured":"Rausch, L. & Kallies, A. Molecular mechanisms governing CD8 T-cell differentiation and checkpoint inhibitor response in cancer. Annu. Rev. Immunol. 43, 515\u2013543 (2025).","journal-title":"Annu. Rev. Immunol."},{"key":"2746_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8(+) T-cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2746_CR27","volume":"12","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Mitochondrial regulation of CD8(+) T cells: mechanisms and therapeutic modulation. Adv. Sci. (Weinh.) 12, e03095 (2025).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2746_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","volume":"10","author":"E Montauti","year":"2024","unstructured":"Montauti, E., Oh, D. Y. & Fong, L. CD4(+) T cells in antitumor immunity. Trends Cancer 10, 969\u2013985 (2024).","journal-title":"Trends Cancer"},{"key":"2746_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139905","volume":"131","author":"G Noel","year":"2021","unstructured":"Noel, G. et al. Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. J. Clin. Invest. 131, e139905 (2021).","journal-title":"J. Clin. Invest."},{"key":"2746_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud, J. L., Houel, A., Panouillot, M., Riffard, C. & Dieu-Nosjean, M. C. Tertiary lymphoid structures in anticancer immunity. Nat. Rev. Cancer 24, 629\u2013646 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2746_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat. Med 29, 593\u2013604 (2023).","journal-title":"Nat. Med"},{"key":"2746_CR32","doi-asserted-by":"publisher","first-page":"e002273","DOI":"10.1136\/jitc-2020-002273","volume":"9","author":"KT Lynch","year":"2021","unstructured":"Lynch, K. T. et al. Heterogeneity in tertiary lymphoid structure B cells correlates with patient survival in metastatic melanoma. J. Immunother. Cancer 9, e002273 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2746_CR33","volume":"6","author":"F Peyraud","year":"2025","unstructured":"Peyraud, F. et al. Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside. Medicines 6, 100546 (2025).","journal-title":"Medicines"},{"key":"2746_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.trecan.2024.12.002","volume":"11","author":"J Hochstadt","year":"2025","unstructured":"Hochstadt, J., Martinez Pacheco, S. & Casanova-Acebes, M. Embracing diversity: macrophage complexity in cancer. Trends Cancer 11, 351\u2013364 (2025).","journal-title":"Trends Cancer"},{"key":"2746_CR35","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","volume":"26","author":"M Shakiba","year":"2025","unstructured":"Shakiba, M. & Tuveson, D. A. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nat. Immunol. 26, 678\u2013691 (2025).","journal-title":"Nat. Immunol."},{"key":"2746_CR36","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.trecan.2025.04.012","volume":"11","author":"Z Xia","year":"2025","unstructured":"Xia, Z. & De Wever, O. The plasticity of cancer-associated fibroblasts. Trends Cancer 11, 770\u2013789 (2025).","journal-title":"Trends Cancer"},{"key":"2746_CR37","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S Bohm","year":"2015","unstructured":"Bohm, S. et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J. Clin. Oncol. 33, 2457\u20132463 (2015).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02746-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02746-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02746-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:02:31Z","timestamp":1783105351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02746-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2746"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02746-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}